Vaccines Highly Effective Against COVID-19 in Obese Individuals
New research has shown that vaccines are highly effective against COVID-19 hospitalization and death in individuals with and without obesity. The Centers for Disease Control and Prevention (CDC) has identified obesity as a high-risk condition and recommended prioritization for vaccination. Obesity is a recognized risk factor for increased morbidity and mortality in persons with COVID-19.
Vaccines from Pfizer, Moderna, Johnson & Johnson, and AstraZeneca are designed to prevent severe COVID-19 in people with and without obesity, except for AstraZeneca where efficacy is not yet known. Studies have shown that the Moderna vaccine has an efficacy of 95.8% in participants with obesity and 91.2% in those with severe obesity. The Pfizer vaccine showed an efficacy of 95.4% among participants with obesity compared to 94.8% among participants without obesity. The Johnson & Johnson vaccine efficacy was 66.8% and 65.9% in participants with obesity 14 and 28 days after dose one, respectively. The Obesity Society encourages individuals with obesity to undergo vaccination with any available vaccine as soon as they are able, due to the increased risk of severe disease and death.
In conclusion, vaccines from Pfizer, Moderna, Johnson & Johnson, and AstraZeneca are recommended for individuals with obesity to prevent severe COVID-19. The Obesity Society encourages vaccination, and it is important for individuals to stay informed about the latest guidelines from global health organizations.
